Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 18, 2022
Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET.
Journal: mAbs
Published: October 01, 2021
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Journal: Nature metabolism
Published: April 15, 2020
Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
Journal: Pediatric blood & cancer
Published: February 19, 2020
Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Journal: Biomolecules
Published: July 21, 2019
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Journal: Journal for immunotherapy of cancer
Published: February 08, 2019
PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive 64Cu-labelled polymers.
Journal: Nature biomedical engineering
Published: August 28, 2018
Breast Tumor Microcalcification Induced by Bone Morphogenetic Protein-2: A New Murine Model for Human Breast Tumor Diagnosis.
Journal: Contrast media & molecular imaging
Published: May 21, 2018
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Journal: The Journal of clinical investigation
Published: July 05, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026